Ramucirumab Treatment for Unresectable Advanced Hepatocellular Carcinoma-A Review of Clinical Trial Data and Real-World Evidence in Japan

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Liver Cell Carcinoma 100%
• Ramucirumab 100%
• Sorafenib 42%
• Alpha Fetoprotein 28%
• Disease 14%
• Adverse Event 14%
• Chemotherapy 14%

Keyphrases

• Expansion Cohort 14%
• Japan Society of Hepatology 14%
• Clinical Practice Guidelines for Hepatocellular Carcinoma 14%

Medicine and Dentistry

• Clinical Hepatology 14%